To date, ET-A antagonists have been extensively studied as anti-cancer therapeutics for various malignancies with promising results [58–61]; however, recent animal studies have revealed that local administration of ET-A antagonists function to attenuate mechanical allodynia and thermal hyperalgesic responses [62–64]. The gene discussed is EDNRA; the disease is cancer.